Fighting Type-2 Diabetes: Present and Future Perspectives
-
Published:2019-06-20
Issue:10
Volume:26
Page:1891-1907
-
ISSN:0929-8673
-
Container-title:Current Medicinal Chemistry
-
language:en
-
Short-container-title:CMC
Author:
Yu Cai-Guo1, Fu Ying1, Fang Yuan1, Zhang Ning1, Sun Rong-Xin1, Zhao Dong1, Feng Ying-Mei1, Zhang Bao-Yu1
Affiliation:
1. Beijing Key Laboratory of Diabetic Prevention and Research, Department of Endocrinology, Lu He hospital, Capital Medical University, Beijing 100149, China
Abstract
Background:
Type-2 diabetes mellitus accounts for 80-90% of diabetic patients.
So far, the treatment of diabetes mainly aims at elevating insulin level and lowering glucose
level in the peripheral blood and mitigating insulin resistance. Physiologically, insulin secretion
from pancreatic β cells is delicately regulated. Thus, how insulin-related therapies could
titrate blood glucose appropriately and avoid the occurrence of hypoglycemia remains an important
issue for decades. Similar question is addressed on how to attenuate vascular complication
in diabetic subjects.
Methods:
We overviewed the evolution of each class of anti-diabetic drugs that have been
used in clinical practice, focusing on their mechanisms, clinical results and cautions.
Results:
Glucagon-like peptide-1 receptor agonists stimulate β cells for insulin secretion in
response to diet but not in fasting stage, which make them superior than conventional insulinsecretion
stimulators. DPP-4 inhibitors suppress glucagon-like peptide-1 degradation. Sodium/
glucose co-transporter 2 inhibitors enhance glucose clearance through urine excretion.
The appearance of these new drugs provides new information about glycemic control. We update
the clinical findings of Glucagon-like peptide-1 receptor agonists, DPP-4 inhibitors and
Sodium/glucose cotransporter 2 inhibitors in glycemic control and the risk or progression of
cardiovascular disease in diabetic patients. Stem cell therapy might be an alternative tool for
diabetic patients to improve β cell regeneration and peripheral ischemia. We summarize the
clinical results of mesenchymal stem cells transplanted into patients with diabetic limb and
foot.
Conclusion:
A stepwise intensification of dual and triple therapy for individual diabetic patient
is required to achieve therapeutic target.
Funder
Capital Health Research and Development of Special National Natural Science Foundation of China
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmacology,Molecular Medicine,Drug Discovery,Biochemistry,Organic Chemistry
Reference140 articles.
1. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes and cancer: a consensus report. 2. Xu Y, Wang L, He J, Bi Y, Li M, Wang T, Wang L, Jiang Y, Dai M, Lu J, Xu M, Li Y, Hu N, Li J, Mi S, Chen CS, Li G, Mu Y, Zhao J, Kong L, Chen J, Lai S, Wang W, Zhao W, Ning G. Prevalence and control of diabetes in Chinese adults. 3. Collaboration NCDRF. Effects of diabetes definition on global surveillance of diabetes prevalence and diagnosis: a pooled analysis of 96 population-based studies with 331,288 participants. 4. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang YH, Stevens GA, Rao M, Ali MK, Riley LM, Robinson CA, Ezzati M. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. 5. Yu K, Zhao D, Feng YM. Targeting obesity for the treatment of type 2 diabetes mellitus.
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|